Nefiracetam
A racetam studied for post-stroke apathy and depression and for cognitive impairment. Some randomised human data exists, but development was limited partly by preclinical toxicity signals in animals.
01 Overview
Nefiracetam is a pyrrolidinone nootropic investigated in Japan and the US, including trials in post-stroke apathy and depression and in Alzheimer's-type impairment. Results were mixed, and its development was constrained after canine and other animal studies raised testicular toxicity concerns at high doses.
It is sold as a research chemical. Users take it for claimed memory and mood benefits, but the safety database in humans is thin and long-term data is lacking.
02 Mechanism
Reported to potentiate GABAergic and cholinergic transmission and to modulate NMDA-receptor and calcium channel activity; the dominant mechanism is not settled.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 150–300 mg/day | Oral | Trials used up to 900 mg/day in divided doses. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Reduced post-stroke apathySignal seen in a controlled trial of stroke patients; not generalisable to healthy users. | Clinical | ||
| Cognitive supportMemory effects shown mainly in animal models. | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HeadacheRacetam-class headache. | Mild | Uncommon | Anecdotal | |
| Potential reproductive toxicityHigh-dose animal studies reported testicular changes; human relevance is uncertain but a reason for caution. | Moderate | Unknown in humans | Preclinical |